The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

Steven M. Horwitz, Owen A. O'Connor, Barbara Pro, Tim M. Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana A. Feldman, Anne Lennard, David Belada, Arpad Illes, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei R. ShustovAndreas Huettmann, Kerry J. Savage, Sam Yuen, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Truemper

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind132
Udgave nummerSuppl. 1
ISSN0006-4971
DOI
StatusUdgivet - 29. nov. 2018
Begivenhed60th ASH Annual Meeting - San Diego, USA
Varighed: 1. dec. 20184. dec. 2018

Konference

Konference60th ASH Annual Meeting
LandUSA
BySan Diego
Periode01/12/201804/12/2018

Bibliografisk note

60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 01-04, 2018

Citationsformater